Systematic review: lamivudine prophylaxis for chemotherapy‐induced reactivation of chronic hepatitis B virus infection
Holbrook E K Kohrt, Daniel L. Ouyang, Emmet B. Keeffe · Alimentary Pharmacology & Therapeutics · 2006
BACKGROUND: Reactivation of hepatitis B virus infection in asymptomatic hepatitis B surface antigen carriers undergoing chemotherapy or immunosuppressive therapy is a well-documented and potentially fatal complication. Data supporting the use of lamivudine for primary prophylaxis have emerged, but its use remains controversial and is not standardized. AIM: To review current randomized-controlled trials, randomized trials and prospective case series to provide a clinically applicable, evidence-based recommendation. METHODS: The published literature was identified using a MEDLINE/PubMed search with secondary review of cited publications, and inclusion of all prospective studies. RESULTS: In nine prospective trials and one randomized-controlled trial, the rate of hepatitis among subjects receiving lamivudine prophylaxis ranged from 0% to 20% (16 of 173, 9.2%), compared with 33-67% among controls. Of patients receiving prophylaxis, 0-24% (15 of 173, 8.7%) developed hepatitis B virus reactivation, compared with 29-56% of controls. Three reactivation-related mortalities were reported (one receiving prophylaxis, two controls). No patients withdrew secondary to toxicity or development of lamivudine-resistant mutations. CONCLUSIONS: The available data show a four- to sevenfold decrease in the rate of hepatitis and hepatitis B virus reactivation in patients who receive lamivudine prophylaxis. It is thus recommended that all hepatitis B surface antigen carriers receive lamivudine, or a comparable anti-viral agent, as prophylaxis from the initiation of chemotherapy until at least 1 year following its completion.
Cited by 123 works. doi:10.1111/j.1365-2036.2006.03081.x Open-access PDF
Authors
References
- A One-Year Trial of Lamivudine for Chronic Hepatitis B
- Hepatitis B Virus Infection
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
- Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
- Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy
- Reactivation of Chronic Hepatitis B Virus Infection by Cancer Chemotherapy
- Spontaneous reactivation of chronic hepatitis B virus infection
- Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors
- Chronic hepatitis B: Update of recommendations† ‡
- Long-term safety of lamivudine treatment in patients with chronic hepatitis B